Biosimilars Month in Review: May 2024

The biosimilars month in review highlights the expansion of treatment options for patients with chronic inflammatory diseases. Recent US Food and Drug Administration (FDA) approvals signify significant progress in biologic therapies, potentially enhancing outcomes and improving access to treatment. Additionally, studies on biosimilars such as CT-P13 demonstrated comparable efficacy and safety to reference biologics, underscoring the importance of biosimilar adoption in maintaining positive treatment outcomes and patient satisfaction in chronic conditions like Crohn's disease.